PF588 SIGNIFICANT POM EFFECT ON THE IMMUNE‐CELL PROFILES IN B, T AND NK SUBSETS IN A LARGE COHORT CLINICAL TRIAL IN RELAPSED/REFRACTORY MYELOMA
Rao Prabhala, Nikhil C. Munshi(Dana-Farber Cancer Institute), Megan Stekla, Puru Nanjappa, Michael Buonopane(Harvard University), Anjan Thakurta(University of Oxford), Meletios Α. Dimopoulos(Korea University), Chaitanya Yenumula, Tsvetan Biyukov(Bristol-Myers Squibb (Switzerland)), Mehmet Samur(Dana-Farber Cancer Institute), Sarbari Acharya, Paul G. Richardson(Harvard University), Raphaël Szalat(Boston University), Alexander T. Heubeck(Harvard University), Mariateresa Fulciniti(Dana-Farber Cancer Institute), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), Albert Oriol Rocafiguera(Institut Català d'Oncologia), William E. Pierceall(Bristol-Myers Squibb (Switzerland)), Salman Hussain(European CanCer Organisation), Sohan Talluri, Meral Beksaç(Liv Hospital), J F Daley, Kevin Hong(Bristol-Myers Squibb (Switzerland)), K. Anderson, Teresa Peluso(Bristol-Myers Squibb (Switzerland)), Maria Teresa Cibeira López, Suzan Lazo-Kallanian(Harvard University)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k